Request information on the availability of this model.
This model is being distributed by The Jackson Laboratory on behalf of the Lymphoma Xenograft core at Dana-Farber Cancer Institute (DFCI).
Additional information can be found by registering at DFCI's PRoXe (https://www.proxe.org/) web site.
PRoXe model id: DFAM-22359-V1
The use of this material by a company is subject to the terms of the attached notice.
The use of this material by an academic institution is subject to the terms of the attached notice.
PDX Model Summary
|
Model Details |
- Model ID
- J000106132
- Initial Diagnosis
- Acute myeloid leukemia
- Final Diagnosis
- Acute myeloid leukemia
- Stage/Grade
- no data
- Primary Site
- Bone marrow
- Sample Site
- Bone marrow
- Tumor Type
- Recurrent/Relapse
|
Publications citing this model |
Procter, JL; et al. Single Doses of Antibody Drug Conjugates (ADCs) Targeted to CD117 or CD45 Have Potent In Vivo Anti-Leukemia Activity and Survival Benefit in Patient Derived AML Models. Blood 2018;132:3316. doi.org/10.1182/blood-2018-99-112726
|
Patient |
- Sex
- Female
- Age (at time of tissue collection)
- 44
- Race/Ethnicity
- White / Not Reported
- Treatment Naïve?
- No
- Current Smoker/Former Smoker
- no data
|
Engraftment |
- Host Strain
- no data
- Sample Type
- Bone marrow aspirate
- Engraftment Site
- no data
|